Kornimate/medical-research-clean huggingface dataset:
characteristics of critically ill covid 19 patients

Conditions: COVID19

Summary: covid19 is n outbreak with unpredictable outcome


Eligibility criteria:
inclusion criteria: * covid 19 patients need oxygen therapy exclusion criteria: * patients does not need oxygen therapy
invision - an observational study to explore effectiveness, tolerability and safety of paliperidone er in patients with schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to explore efficacy, tolerability and safety of paliperidone extended release (er) in 250 schizophrenia patients who started treatment with paliperidone er in a naturalistic setting.

this is an observational, prospective, multicenter 6-month study to explore efficacy, tolerability and safety of paliperidone extended release (er) in 250 schizophrenia patients who started treatment with paliperidone er in a naturalistic setting. the primary objective is to explore changes in clinical global impression of severity (cgi-s) score from baseline up to 26 weeks, in subgroups of schizophrenia patients who started treatment with paliperidone er. secondary objectives are: 1) to explore changes in mental health and social functioning based on routine outcome assessments in the netherlands, the health of the nation outcome scales (honos) and global assessment of functioning (gaf), in schizophrenia patients who started treatment with paliperidone er ; 2) to explore changes in patient's satisfaction with treatment, changes in number of ambulant contacts, changes in body weight, changes in concomitant therapy and to explore adverse events in schizophrenia patients who started treatment with paliperidone er; and to explore possible association between cgi-s, gaf and honos. the patients will receive paliperidone er (6 mg, 9 mg or other dosages as directed on the label) once daily for the period of 6 month. which dosage of paliperidone er the patients receive will be at the discretion of the investigator and according the summary of product characteristics (smpc). because the study is observational, dosage, administration and duration of treatment is at discretion of treating physician.

Eligibility criteria:
inclusion criteria: * patient meets the dsm-iv criteria for schizophrenia * switched to or started on paliperidone er, not longer than two weeks ago * in 24 hours before initiation of paliperidone er treatment, cgi-s, patient satisfaction with treatment, concomitant therapy, body weight, gaf and honos data are available * patient or legal representative has signed the informed consent form within two weeks after starting treatment with paliperidone er exclusion criteria: * no use of paliperidone er, clozapine, any conventional depot neuroleptic or long acting atypical antipsychotic drugs during 3 months before starting paliperidone er * no participation in an investigational drug trial in 30 days prior to starting paliperidone er * no history of neuroleptic malignant syndrome * no known hypersensitivity to paliperidone er or risperidone * no patients hospitalized for a period longer than 12 weeks

Keywords: paliperidone er schizophrenia
uk validation of the automated "accexible" speech analysis software

Conditions: Mild Cognitive Impairment and Dementia

Summary: dementia, especially dementia caused by alzheimer's disease, is considered one of the most severe health problems of our time. it is currently known that the disease begins many years before clinical symptoms appear. the sooner the patient is diagnosed, the sooner the patient will be in a position to prevent further deterioration. a recent orientation is the analysis of language in relation to the description of images with a high and varied semantic and emotional content. it can be studied that changes in the description of an image check if these changes are associated with the evolution of a person with probable impairment both in memory and cognitive as well as emotional, psychiatric, behavioral and even in their interaction with environmental factors especially those associated with socialization and loneliness. the present study has the objective of validating a digital method for detection and follow-up of patients with mild cognitive impairment (mci) or dementia in a memory clinic setting.


Eligibility criteria:
inclusion criteria for patients: * adult patients 55+ years of age with suspected mci or diagnosis of dementia referred into secondary care memory clinic by their general practitioner. * have english as first language (able to speak and understand verbal messages). * patients must have agreed to participate in the study and have voluntarily signed the informed consent. inclusion criteria for healthy volunteers: * healthy older adults (55+ years of age), without a diagnosis neurological, or psychiatric disorders or any clinical evidence of cognitive decline. * have english as first language (able to speak and understand verbal messages). * controls must have agreed to participate in the study and have voluntarily signed the informed consent. exclusion criteria for patients: * to have received a diagnosis of a significant psychiatric disorder or other cognitive impairment not due to neurodegeneration. * to have significant vision problems that would affect the ability to perceive visual stimuli. * to have significant hearing problems that would affect the ability to understand verbal cues. * to be unable to give informed consent to participate in the study. exclusion criteria for healthy volunteers: * objective evidence of significant cognitive decline in any one domain. * score of \<88 on ace-iii cognitive testing.
efficacy and safety of the algorithm for enteral nutrition support

Conditions: Nutrition Disorder, Child

Summary: the purpose of this trial is to evaluate the efficacy and safety of the implementation of an algorithm for enteral nutrition support compared with usual standard practice in children with malnutrition status with congenital heart disease

in many developing countries, pediatric cardiac programs are not fully established, and nutrition support algorithm is lack. therefore, this study aimed to evaluate the the efficacy and safety of the implementation of an algorithm for enteral nutrition support compared with usual standard practice in children with malnutrition status with congenital heart disease. the usual standard practice for feeding often interrupted by retention in the gut and then choose the parenteral nutrition support especially in the patients with unstable hemodynamic status. actually tiny and continuous feeding would improve the gut function and reach the adequate energy supply.

Eligibility criteria:
inclusion criteria: weight-for-age of z-score \<-2; or length-for-age of z score \<-2; or weight-for-length of z score \<-2 exclusion criteria: any patient with congenital genetic metabolic diseases
molecular signatures of esophageal atresia

Conditions: Esophageal Atresia

Summary: although several studies have revealed signaling pathways as well as genes potentially involved in the development of esophageal atresia (ea), our understanding of the pathophysiology of ea lags behind improvements in the surgical and clinical care of patients born with this anomaly. however, a causative genetic abnormality can be identified in less than 10% of patients, even using more recent next-generation sequencing techniques. as most cases of ea associated with tracheoesophageal fistula (tof) are sporadic, and the familial recurrence rate is low (1%), this suggests that epigenetic and environmental factors also contribute to the disease. further investigations are needed to better understand the mechanisms underlying ea. that information can come from the oesophageal biopsies that are collected in routine care and long-term storage at the hospital. however, the impact of the length of the storage is still unknown.


Eligibility criteria:
inclusion criteria: * anastomosis group : born with esophageal atresia anastomosis performed in lille hospital parents consent - control group : born with esophageal atresia exclusion criteria: * both groups : parents refusing to participate in the study

Keywords: esophageal atresia epigenetic proteomics metabolomics
post market surveillance study of the wingspan stent system

Conditions: Intracranial Atherosclerosis

Summary: the primary objective of this study is to evaluate the rate of stroke and/or death in patients treated with the wingspan stent system, according to the indications for use, within 72 hours post procedure.

this research study is a food and drug administration (fda) mandated post market surveillance study of the wingspan® stent system, also known as the weave™ trial. the purpose of this trial is to fulfill a fda requirement to evaluate the rate of stroke and/or death within 72 hours of the procedure, in patients who have a wingspan stent implanted in accordance with the indications for use.

Eligibility criteria:
all patients for whom treatment with the wingspan stent system is considered.

Keywords: wingspan stent system wingspan stent intracranial stent ischemic stroke intracranial atherosclerotic disease intracranial stenosis
efficacy of a collagen hemostatic dressing after tooth extraction

Conditions: Tooth Avulsion

Summary: this study is a multicentric randomised (2 groups, ratio 1:1) post market clinical follow-up trial. 38 subjects (teeth) requiring a simple tooth extraction or multiple tooth extraction on the same quadrant and taking curative or preventive antithrombotic treatment will be included (19 in each group). the aim of the study is to assess the efficacy of etik collagene (topical hemostatic collagen-product) on the hemostasis (time to stop bleeding) after tooth extraction. the hemostasis is measured by assessing the presence of bleeding within the first 8 minutes post-extraction. group 1: intra-alveolar placement of etik collagene immediately after tooth extraction. group 2: the alveolus is left empty after tooth extraction (the use of etik collagene is delayed 8 minutes after tooth extraction, before suture). subjects will be followed-up to 7 days.


Eligibility criteria:
inclusion criteria: * male or female, age \> 18 years old, * patient undergoing a simple tooth extraction or multiple tooth extraction on the same quadrant, * patient taking curative or preventive antithrombotic treatment or patient with a moderate thrombocytopenia, * patient reachable after surgery, * signed informed consent form, * subject affiliated to a health insurance system, or is a beneficiary. exclusion criteria: * known allergy to bovine collagen, * preoperative inr\ 3 or instable, * patient with high risk of bleeding, history of postoperative hemorrhagic complication, * treatment with bone resorption inhibitor, or patient irradiated at the cervico-facial level, * contraindication to anesthesia using articaine with 1:200,000 epinephrine, * clinical follow-up expected to be difficult, * presence of uncontrolled hypertension, uncompensated diabetes or other clinically relevant systemic alterations, * current participation in another clinical trial or subject still within the exclusion period of a previous clinical trial, * vulnerable subjects.

Keywords: hemostasis tooth extraction oral surgery human
the efficiency and safety of sodium bicarbonate on uric acid in patients with asymptomatic hyperuricemia or gout

Conditions: Asymptomatic Hyperuricemia; Gout

Summary: this study evaluate the serum uric acid lowering effect of sodium bicarbonate as well as its safety in patients with asymptomatic hyperuricemia or gout. half of the participants will receive sodium bicarbonate only, while the other half receive none.


Eligibility criteria:
inclusion criteria: 1. sign informed consent form; 2. serum uric acid ≥420mmol/l; 3. within the age range of 18-65 years old; 4. within the bmi range of 18-30kg/m2; 5. both men and women are eligible exclusion criteria: 1. general situations * pregnancy or lactation； * participants who can't take contraception during the study or within one month after the completion of the intervention; * situations which will harm the participants; * participants with bad compliance. 2. taking part in another trail 3. gout flares happening over the last one month; 4. administration of medications over the last one month, including: allopurinol, febuxostat,benzbromarone, and/or sodium bicarbonate； 5. urine ph\>7.0; 6. hepatic function：alt and/or ast and/or tb\>1.5 upper limit of normal (uln); 7. renal function：egfr\ 0.5g/24h； 8. hypertension：\>140/90mmhg; 9. type 2 diabetes or taking drugs for lowering glucose (not including prediabetes); 10. urinary stone,urinary infection; 11. taking drugs ove the last one month and during the trial, including：thiazide diuretic, loop diuretics, pyrazinamide,ethambutol, tacrolimus, niacin, aspirin, estrogen, losartan, amlodipine, reserpine, vitamin c，fenofibrate，atorvastatin， sulfonylureas，biguanides，nsaids; 12. disease which influence serum uric acid, such as cancer, lymphoma, and etc. 13. severe disorders involving heart, liver, kidneys, brain, lungs,digestive tract, rheumatoid disease, blood, endocrine, infection, and etc; 14. blood donation or excessive loss of blood over the last 3 month.
resolving grief after spinal cord injury

Conditions: Spinal Cord Injury

Summary: the purpose of this study is to examine the usefulness of the grief recovery method in assisting persons with spinal cord injuries to achieve as complete a recovery as possible, thereby allowing for fuller participation in life.


Eligibility criteria:
inclusion criteria: \* persons with a spinal cord injury who are willing to participate in the program. exclusion criteria: \* unable or unwilling to participate.
use of autologous, adult adipose-derived stem/stromal cells in chronic lung disorders

Conditions: Lung Disease

Summary: chronic obstructive pulmonary disease (copd) is a lung-related disorder that is characterized by long-term, often progressive state of poor airflow. primary symptoms include low oxygen tension, shortness of breath, productive cough, and broncho-pulmonary inflammation and interference with oxygen-carbon dioxide exchange. air pollution and tobacco smoking are felt to be the most common cause of these issues. diagnostic testing is based on poor airflow measured by lung function studies and whose symptoms do not improve much with antiasthma bronchodilators. study is an interventional study to document the safety and efficacy of use of ad-csvf in chronic broncho-pulmonary disease groups.

copd is often treated by limiting exposure to poor air quality, but there is no cure at this time. attempted therapy include smoking cessation, vaccinations, respiratory rehabilitation, and attempts of use of bronchodilators and steroids. many resort to supplemental oxygen therapy, lung transplantation, and antibiotic supportive therapy during exacerbations. as of 2013, copd involve approximately 5% pf the global populations (approximately 330 million). most commonly it occurs approximately equally between men/women and result in about 3 million deaths per year. estimates of economic costs are estimated to be more than 2.1 trillion dollars in 2010. this study includes microcannula harvesting of subdermal adipose tissues, incubation, digestion and isolation of ad-csvf. this stromal cellular pellet (without actual extracellular matrix or stromal elements) is then suspended in 500 cc sterile normal saline (ns) and deployed via peripheral intravenous route. evaluations of safety issues are measured at intervals (both severe and non-severe categories) and by repeated pulmonary function studies.

Eligibility criteria:
inclusion criteria: * prior diagnosis of moderate to severe copd * gold ii a, iii, iv exclusion criteria: * pregnant or lactating females * life expectancy of \< 3 months due to concomitant illnesses * exposure to any investigational drug or procedure with 1 month prior to study entry or enrollment in concurrent study which may interfere with interpretation of study results * illness which, in investigators judgement, may interfere with the patient' ability to comply with protocol, compromise patient safety, ability to provide informed consent to study, or interfere with interpretation of study outcomes * subjects on chronic immunosuppressive or chemotherapeutic medications * known drug or alcohol dependence or other factors which may interfere with study conduct or interpretation of result or in the opinion of investigator are not suitable to participate. * subjects with documented alpha-1 antitrypsin deficiency (inherited lung and liver disorder) * unwilling or not competent to understand and execute an informed consent agreement * patients positive for hepatitis (hepatitis a history excepted)

Keywords: copd, emphysema
risk factors analysis for acute myocardial infarction patients

Conditions: AMI - Acute Mesenteric Ischemia; Extracorporeal Membrane Oxygenation Complication

Summary: ecmo has been used to save the lives of many critically ill patients with cardiorespiratory dysfunction as important rescue therapy. though the proportion of ecmo applied to this population has been increasing year by year, clinical outcomes of ami remain poor with high in-hospital mortality. thus, it is necessary to characterize clinical features and investigate potentially modifiable factors contributing to outcomes of ami patients who received ecmo treatment.


Eligibility criteria:
inclusion criteria: clinical diagnosis of alzheimer's disease age more than 18 exclusion criteria: life expectancy \ 60 min) iatrogenic myocardial infarction secondary to a percutaneous coronary intervention va-ecmo implanted in another center before admission
patient reported outcomes after oncoplastic breast conserving surgery

Conditions: Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer in Situ

Summary: the goal of this study is to assess patient satisfaction after oncoplastic breast conserving surgery. with the help of a breast-questionnaire the patient satisfaction will be assessed before the surgery and 4 weeks, 6 months and 1 year after the operation. the main question it aims to answer are: does breast conserving surgery improve quality of life. type of study: cohort study, observational ocbs = oncoplastic breast conserving surgery bct = breast conserving therapy dcis = ductal carcinoma in situ participant population/health conditions * patients with newly diagnosed breast cancer, that can be treated breast conserving * the participants have to be at least 18 years old participants will fill out a questionnaire pre surgery, 4 weeks, 6 months and 1 year after the surgery. the individual questionnaires will be compared.

the management of breast cancer has undergone a significant shift over the last century. the advances in systemic therapy have not only improved the overall prognosis however also allowed for less radical surgery and more breast conservable efforts. the term oncoplastic breast conserving surgery was first coined in the early 90s where breast cancer surgery was performed while incorporating plastic surgical techniques. therefore, this enabled the preservation of the natural breast shape with good aesthetic outcomes. over the years oncoplastic breast conserving surgery has become widely accepted and adopted into routine clinical practice by most breast cancer surgeons. the oncological safety surrounding oncoplastic breast conserving surgery have been well established. rates of positive surgical margins and re-excision rates have been shown to be similar to traditional lumpectomy operations. complication rates are also comparable and oncoplastic breast conserving surgery does not result in delays in adjuvant treatments. however, many surgeons would concur that the most significant benefit of oncoplastic breast conserving surgery (obcs) is patient satisfaction and the potential improvement in their quality of life. patient reported outcomes (proms) allow us to objectively assess patient satisfaction and the impact the intervention has had onto their lives. incorporating proms into daily clinical practice would not only facilitate shared-decision making but also allow us to tailor clinical management to suit individual patient needs. this study however also aims to assess the patient reported outcome after breast surgery and in the follow up time (after radiotherapy, ...).

Eligibility criteria:
inclusion criteria: * bct oncoplastic surgery technique * women \> 18 years exclusion criteria: * previously treated ipsilateral breast cancer or dcis * severe psychological illness by doctors' discretion (as taking part in a study could increase anxiety) or severe dementia, that stops them to consent to the procedure * pregnant women * distant metastatic disease (m1)
high-sensitivity cardiac troponin on presentation to rule out myocardial infarction

Conditions: Acute Coronary Syndrome; Myocardial Infarction

Summary: patients with suspected acute coronary syndrome account for a tenth of all presentations to the emergency department and up to 40 per cent of unplanned hospital admissions. the majority of patients do not have a heart attack (myocardial infarction), and may be safely discharged from the emergency department. the investigators propose to evaluate whether the use of the highsteacs pathway in patients with suspected acute coronary syndrome reduces length of stay and allows more patients to be safely discharged from the emergency department. this pathways utilizes high-sensitivity cardiac troponin i testing and will rule out myocardial infarction if troponin concentrations are \<5 ng/l on presentation, with further testing indicated at 3 hours only in those presenting early or with troponin concentrations between 5 ng/l and the 99th centile. in six secondary and tertiary centres across scotland, the investigators will introduce the pathway as part of a stepped wedge cluster randomized controlled trial. sequential hypothesis testing will evaluate the efficacy and safety of the pathway. the primary efficacy end-point will be length of stay from time of presentation until final hospital discharge and the primary safety end-point will be survival free from type 1 or 4b myocardial infarction or cardiac death from discharge to 30 days. the study population will consist of those patients with cardiac troponin concentrations within the normal reference range (\<99th centile) at presentation.


Eligibility criteria:
inclusion criteria: * all consecutive patients with suspected acute coronary syndrome * high-sensitivity cardiac troponin i measured as part of routine clinical care exclusion criteria: * patients who are not resident in scotland * patients with st-segment elevation myocardial infarction * patients presenting to hospital in cardiac arrest * patients with presentation high-sensitivity cardiac troponin i concentrations greater than sex-specific 99th centile thresholds

Keywords: high-sensitivity cardiac troponin i myocardial infarction acute coronary syndrome cluster-randomized trial